PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28184999-11	2017	Radiation-induced expression of gamma-H2AX was increased and that of RAD51 was decreased by ROSI pre-treatment in ME-180 cells, but not in HeLa cells.	Rosiglitazone	92-96	RAD51 recombinase	Homo sapiens	69-74	
28184999-12	2017	ROSI increases radiosensitivity by inhibiting RAD51-mediated repair of DNA damage in some cervical cancer cell lines; therefore, ROSI is a potential inhibitor of RAD51 that can be used to enhance the effect of RT in the treatment of some cervical cancers.	Rosiglitazone	0-4	RAD51 recombinase	Homo sapiens	46-51	
28184999-12	2017	ROSI increases radiosensitivity by inhibiting RAD51-mediated repair of DNA damage in some cervical cancer cell lines; therefore, ROSI is a potential inhibitor of RAD51 that can be used to enhance the effect of RT in the treatment of some cervical cancers.	Rosiglitazone	0-4	RAD51 recombinase	Homo sapiens	162-167	
28184999-12	2017	ROSI increases radiosensitivity by inhibiting RAD51-mediated repair of DNA damage in some cervical cancer cell lines; therefore, ROSI is a potential inhibitor of RAD51 that can be used to enhance the effect of RT in the treatment of some cervical cancers.	Rosiglitazone	129-133	RAD51 recombinase	Homo sapiens	46-51	
28184999-12	2017	ROSI increases radiosensitivity by inhibiting RAD51-mediated repair of DNA damage in some cervical cancer cell lines; therefore, ROSI is a potential inhibitor of RAD51 that can be used to enhance the effect of RT in the treatment of some cervical cancers.	Rosiglitazone	129-133	RAD51 recombinase	Homo sapiens	162-167